Edwards Lifesciences Corp/ US28176E1082 /
| 15/11/2024 20:06:12 | Chg. +0.95 | Volume | Bid20:06:16 | Ask20:06:16 | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 67.11USD | +1.44% | 2.7 mill. Turnover: 136.58 mill. |
67.09Bid Size: 700 | 67.12Ask Size: 700 | 39.67 bill.USD | - | 29.12 |
Assets
|
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
2021 US GAAP in mill. USD |
2022 US GAAP in mill. USD |
2023 US GAAP in mill. USD |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Property and Equipment | 1,060.3000 | 1,395.2000 | 1,546.6000 | 1,632.8000 | 1,749.4000 | ||||||
| Intangible Assets | 336.5000 | 331.4000 | 323.6000 | 285.2000 | 428.4000 | ||||||
| Long-Term Investments | 585.5000 | 801.6000 | 1,834.2000 | 1,239 | 583.9000 | ||||||
| Fixed Assets | 3,504.1000 | 4,146.1000 | 5,321.9000 | 5,196.7000 | 5,327.5000 | ||||||
| Inventories | 640.9000 | 802.3000 | 726.7000 | 875.5000 | 1,168.2000 | ||||||
| Accounts Receivable | 543.6000 | 514.6000 | 582.2000 | 643 | 775.1000 | ||||||
| Cash and Cash Equivalents | 1,179.1000 | 1,183.2000 | 862.8000 | 769 | 1,144 | ||||||
| Current Assets | 2,984 | 3,091 | 3,180.7000 | 3,095.8000 | 4,035.7000 | ||||||
| Total Assets | 6,488.1000 | 7,237.1000 | 8,502.6000 | 8,292.5000 | 9,363.2000 | ||||||
Liabilities
|
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
2021 US GAAP in mill. USD |
2022 US GAAP in mill. USD |
2023 US GAAP in mill. USD |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 180.4000 | 196.5000 | 204.5000 | 201.9000 | 201.4000 | ||||||
| Long-term debt | 594.4000 | 595 | 595.7000 | 596.3000 | 597 | ||||||
| Liabilities to Banks | - | - | - | - | - | ||||||
| Provisions | 696.5000 | 670.2000 | 802.3000 | - | - | ||||||
| Liabilities | 2,339.8000 | 2,662.8000 | 2,666.7000 | 2,485.8000 | 2,643.8000 | ||||||
| Share Capital | 654.3000 | 636.4000 | 642 | 646.3000 | 650.5000 | ||||||
| Total Equity | 4,148.3000 | 4,574.3000 | 5,835.9000 | 5,806.7000 | 6,719.4000 | ||||||
| Minority Interests | - | - | - | - | 69.4000 | ||||||
| Total liabilities equity | 6,488.1000 | 7,237.1000 | 8,502.6000 | 8,292.5000 | 9,363.2000 | ||||||
Income Statement
|
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
2021 US GAAP in mill. USD |
2022 US GAAP in mill. USD |
2023 US GAAP in mill. USD |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | 4,348 | 4,386.3000 | 5,232.5000 | 5,382.4000 | 6,004.8000 | ||||||
| Depreciation (total) | - | - | - | - | - | ||||||
| Operating Result | 1,146.8000 | 897.6000 | 1,690.3000 | 1,748.5000 | 1,534.1000 | ||||||
| Interest Income | -11.5000 | -7.6000 | 1 | -16.3000 | -49.6000 | ||||||
| Income Before Taxes | 1,166.5000 | 916.7000 | 1,702 | 1,767.4000 | 1,598.1000 | ||||||
| Income Taxes | 119.6000 | 93.3000 | 198.9000 | 245.5000 | 198.7000 | ||||||
| Minority Interests Profit | - | - | - | - | -3 | ||||||
| Net Income | 1,046.9000 | 823.4000 | 1,503.1000 | 1,521.9000 | 1,402.4000 | ||||||
Per Share
Cash Flow
|
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
2021 US GAAP in mill. USD |
2022 US GAAP in mill. USD |
2023 US GAAP in mill. USD |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow from Operating Activities | 1,179.4000 | 1,054.3000 | 1,732.1000 | 1,218.2000 | 895.8000 | ||||||
| Cash Flow from Investing Activities | -595.8000 | -531.1000 | -1,722.5000 | 252.3000 | 173.8000 | ||||||
| Cash Flow from Financing | -115.6000 | -486.9000 | -356.3000 | -1,584.5000 | -711 | ||||||
| Decrease / Increase in Cash | 465 | 15.8000 | -332.8000 | -94.8000 | 375.4000 | ||||||
| Employees | 13,900 | 14,900 | 15,700 | - | - | ||||||
